Deputy Chief Medical Officer, Biologics and Cell Therapy
David brings to Athenex significant scientific and managerial expertise in the field of translational pharmacology and clinical research. Prior to joining Athenex, David held leadership positions at Merck Research Laboratories and Schering-Plough Research Institute in the Department of Experimental Medicine. During his 30 years in the industry, David has made significant contributions to the successful development and registration of numerous compounds in the areas of Oncology/Immuno-Oncology, Cardiovascular Disease, and Hepatology. His expertise covers the full spectrum of therapeutic modalities including small molecules, liposomal encapsulated compounds, targeted cytotoxic conjugates, cytokines, monoclonal antibodies and gene therapies. At Schering-Plough KK (Tokyo), David was a senior executive in clinical research streamlining the research culture within the organization, resulting in numerous new drug approvals for the Japanese market.
David received his medical degree from the College of Medicine of the University of Saskatchewan. Subsequently he trained in internal medicine at the Mayo Clinic, Rochester and in Endocrinology and Metabolism at the University of Toronto and the University of California, San Diego. David is board certified in Internal Medicine and Endocrinology and Metabolism and is a Fellow of the Royal College of Physicians of Canada.